Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24 – Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...

Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy – The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared...